Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities

References

• Kertesz SG, Gordon AJ. A crisis of opioids and the limits of prescription control: United States. Addiction. 2019;114(1):169–180.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Syst Rev. 2014;(2). doi:10.1002/14651858.CD002207.pub4.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391–394.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158–170.
   PubMed Web of Science ®Google Scholar
• Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1–3):151–157.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456–462.
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8). doi:10.1002/14651858.CD004145.pub4.
   PubMed Web of Science ®Google Scholar
• Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. ScientificWorldJournal. 2005;5:452–468.
   PubMedGoogle Scholar
• Giacomuzzi SM, Riemer Y, Ertl M, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction. 2003;98(5):693–702.
   PubMed Web of Science ®Google Scholar
• Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631–642.
   PubMed Web of Science ®Google Scholar
• Ponizovsky AM, Margolis A, Heled L, Rosca P, Radomislensky I, Grinshpoon A. Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance. Subst Use Misuse. 2010;45(1–2):288–313.
   PubMed Web of Science ®Google Scholar
• Lo-Ciganic WH, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Lo-Ciganic WH, Cochran G, et al. Patterns and quality of buprenorphine opioid agonist treatment in a large medicaid program. J Addict Med. 2015;9(6):470–477.
   PubMed Web of Science ®Google Scholar
• Bentzley BS, Barth KS, Back SE, Aronson G, Book SW. Patient perspectives associated with intended duration of buprenorphine maintenance therapy. J Subst Abuse Treat. 2015;56:48–53.
   PubMed Web of Science ®Google Scholar
• Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015;52:48–57.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Sigmon SC, Strain EC, Heil SH, Higgins ST. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend. 2011;119(1–2):1–9.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1–2):9–15.
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–668.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry. 2020. doi:10.1038/s41380-020-0661-4
   Web of Science ®Google Scholar
• Volkow ND. Personalizing the treatment of substance use disorders. Am J Psychiatry. 2020;177(2):113–116.
   PubMed Web of Science ®Google Scholar
• Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abus. 2018;39(2):139–144.
   PubMed Web of Science ®Google Scholar
• Veterans Health Administration/Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. 2017. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf. Accessed May 1, 2020.
   Google Scholar
• Oliva EM, Trafton JA, Harris AH, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39(2):103–107.
   PubMed Web of Science ®Google Scholar
• Oliva EM, Harris AH, Trafton JA, Gordon AJ. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug Alcohol Depend. 2012;122(3):241–246.
   PubMed Web of Science ®Google Scholar
• Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon AJ. Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Subst Abus. 2018;39(3):286–288.
   PubMed Web of Science ®Google Scholar
• Hagedorn H, Kenny M, Gordon AJ, et al. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addict Sci Clin Pract. 2018;13(1):25.
   PubMedGoogle Scholar
• Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215–224.
   PubMed Web of Science ®Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374–381.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andree T, McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008;17(6):459–462.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Trafton JA, Saxon AJ, et al. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Depend. 2007;90(2–3):292–296.
   PubMed Web of Science ®Google Scholar
• Gellad WF, Good CB, Shulkin DJ. Addressing the opioid epidemic in the United States: lessons from the department of veterans affairs. JAMA Intern Med. 2017;177(5):611.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230–S242.
   PubMed Web of Science ®Google Scholar
• Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1–6.
   PubMed Web of Science ®Google Scholar
• Wen H, Borders TF, Cummings JR. Trends in buprenorphine prescribing by physician specialty. Health Aff (Millwood)). 2019;38(1):24–28.
   PubMed Web of Science ®Google Scholar
• Rubin R. Rural veterans less likely to get medication for opioid use disorder. JAMA. 2020;323(4):300
   Web of Science ®Google Scholar
• Kullgren JT, Fagerlin A, Kerr EA. Completing the MISSION: a blueprint for helping veterans make the most of new choices. J Gen Intern Med. 2020;35(5):1567–1570.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Starrels JL, Tai B, et al. Can substance use disorders be managed using the chronic care model? Review and recommendations from a NIDA consensus group. Public Health Rev. 2014;35(2). doi:10.1007/BF03391707
   PubMedGoogle Scholar
• van Straten A, Hill J, Richards DA, Cuijpers P. Stepped care treatment delivery for depression: a systematic review and meta-analysis. Psychol Med. 2015;45(2):231–246.
   PubMed Web of Science ®Google Scholar
• Moser M. Is the stepped-care approach to the management of hypertension still appropriate? Chest. 1985;88(4):629.
   PubMed Web of Science ®Google Scholar
• Moser M. Initial treatment of adult patients with essential hypertension: I. Why conventional stepped-care therapy of hypertension is still indicated. Pharmacotherapy. 1985;5(4):189–195.
   PubMed Web of Science ®Google Scholar
• Smink AJ, van den Ende CH, Vliet Vlieland TP, et al. "Beating osteoARThritis": development of a stepped care strategy to optimize utilization and timing of non-surgical treatment modalities for patients with hip or knee osteoarthritis. Clin Rheumatol. 2011;30(12):1623–1629.
   PubMed Web of Science ®Google Scholar
• Speed TJ, Parekh V, Coe W, Antoine D. Comorbid chronic pain and opioid use disorder: literature review and potential treatment innovations. Int Rev Psychiatry. 2018;30(5):136–146.
   PubMed Web of Science ®Google Scholar
• Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–431.
   PubMedGoogle Scholar
• LaBelle CT, Han SC, Bergeron A, Samet JH. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): statewide implementation of the massachusetts collaborative care model in community health centers. J Subst Abuse Treat. 2016;60:6–13.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Griffin ML, Potter JS, et al. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? Drug Alcohol Depend. 2014;140:118–122.
   PubMed Web of Science ®Google Scholar
• Weiss RD. Behavioural treatment combined with buprenorphine does not reduce opioid use compared with buprenorphine alone. Evid Based Ment Health. 2014;17(2):e2.
   PubMedGoogle Scholar
• Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–1246.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74 e11.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–374.
   PubMed Web of Science ®Google Scholar
• Harris AH, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013;10(4):410–419.
   PubMed Web of Science ®Google Scholar
• Stetler CB, Damschroder LJ, Helfrich CD, Hagedorn HJ. A Guide for applying a revised version of the PARIHS framework for implementation. Implement Sci. 2011;6:99.
   PubMed Web of Science ®Google Scholar
• Helfrich CD, Damschroder LJ, Hagedorn HJ, et al. A critical synthesis of literature on the promoting action on research implementation in health services (PARIHS) framework. Implement Sci. 2010;5:82.
   PubMed Web of Science ®Google Scholar
• Donaldson NE, Rutledge DN, Ashley J. Outcomes of adoption: measuring evidence uptake by individuals and organizations. Worldviews Evid Based Nurs. 2004;1:S41–S51.
   PubMedGoogle Scholar
• Rycroft-Malone J. The PARIHS framework–a framework for guiding the implementation of evidence-based practice. J Nurs Care Qual. 2004;19(4):297–304.
   PubMed Web of Science ®Google Scholar
• Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–1327.
   PubMed Web of Science ®Google Scholar
• Gaglio B, Shoup JA, Glasgow RE. The RE-AIM framework: a systematic review of use over time. Am J Public Health. 2013;103(6):e38–e46.
   PubMed Web of Science ®Google Scholar
• Hagedorn H, Hogan M, Smith JL, et al. Lessons learned about implementing research evidence into clinical practice. Experiences from VA QUERI. J Gen Intern Med. 2006;21(Suppl 2):S21–S24.
   PubMedGoogle Scholar
• Haley SJ, Pinsker EA, Gerould H, Wisdom JP, Hagedorn HJ. Patient perspectives on alcohol use disorder pharmacotherapy and integration of treatment into primary care settings. Subst Abus. 2019;40(4):1–9.
   PubMed Web of Science ®Google Scholar
• Hagedorn HJ, Brown R, Dawes M, et al. Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. Implement Sci. 2016;11:64
   PubMed Web of Science ®Google Scholar
• Harris AH, Bowe T, Hagedorn H, et al. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addict Sci Clin Pract. 2016;11(1):15.
   PubMedGoogle Scholar